Company News

Orthocell has today published its Quarterly Report for the period ended 31 March 2024.

Orthocell has announced that it has successfully completed the first stage of the Remplir™ US 510(k) market authorisation nerve repair…

Orthocell has today announced that it has completed a Company-led Strategic Placement to raise $3.5 million.

Orthocell has today announced that the Company has submitted a regulatory application to the Health Services Authority of Singapore for…

Orthocell has appointed Australia’s former US ambassador and Governor of Western Australia, The Hon Kim Beazley AC, as an Independent…

Orthocell has today released positive results from our clinical study comparing OrthoATI™ to surgery for the treatment of severe chronic…

Orthocell has today announced the appointment of one of Australia’s most innovative and respected plastic and reconstructive surgeons and researchers,…

Orthocell has today published its Quarterly Report for the period ended 30 September 2023.

Orthocell has announced that Striate+™dental membrane has received regulatory approval under the new European Medical Device Regulations (MDR).

Orthocell was delighted to co-sponsor the inaugural Nerve Transfer and Reconstruction Symposium at the University of Western Australia last week.